Lethality in LPS-induced endotoxemia in C3H/HeCr mice is associated with prevalence of proinflammatory cytokines: Lack of protective action of lactoferrin

FEMS Immunology and Medical Microbiology

Volumn 42, Issue 2, 2004, Pages 167-172

  Zimecki, Michal ^a   Chodaczek, Grzegorz ^a   Kocieba, Maja ^a   Kruzel, Marian L ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Endotoxemia; IFN ; Interleukin 6; Lactoferrin; TNF

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 6; LACTOFERRIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTOXEMIA; ESCHERICHIA COLI; FEMALE; INFECTION SENSITIVITY; LIVER; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SPLEEN; STATISTICAL SIGNIFICANCE; STRAIN DIFFERENCE; SURVIVAL RATE;

ANIMALS; CYTOKINES; ENDOTOXEMIA; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; INTERFERON TYPE II; INTERLEUKIN-6; LACTOFERRIN; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C3H; MICE, INBRED CBA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4444300562     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.femsim.2004.04.003     Document Type: Article

References (27)

1. Mayeux P.R. Pathobiology of lipopolysaccharide. J. Toxicol. Environ. Health. 51:1997;415-435
2. Bradley S.G., Munson A.E., Dewey W.L., Harris L.S. Enhanced susceptibility of mice to combinations of delta 9-tetrahydrocannabinol and live or killed gram-negative bacteria. Infect. Immun. 17:1977;325-329
3. Ghadirian E., Kongshavn P.A. Genetic control of susceptibility of mice to infection with E. histolytica. Parasite Immunol. 6:1984;349-360
4. Glant T.T., Bardos T., Vermes C., Chandrasekaran R., Valdez J.C., Otto J.M., Gerard D., Velins S., Lovasz G., Zhang J., Mikecz K., Finnegan A. Variations in susceptibility to proteoglycan-induced arthritis and spondylitis among C3H substrains of mice: evidence of genetically acquired resistance to autoimmune disease. Arthritis Rheum. 44:2001;682-692
5. Gros P., Skamene E., Forget A. Genetic control of natural resistance to Mycobacterium bovis (BCG) in mice. J. Immunol. 127:1981;2417-2421
6. Baveye S., Elass E., Mazurier J., Spik G., Legrand D. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin. Chem. Lab. Med. 37:1999;281-286
7. Gutteberg T.J., Rokke O., Andersen O., Jorgensen T. Early fall of circulating iron and rapid rise of lactoferrin in septicemia and endotoxemia: an early defence mechanism. Scand. J. Infect. Dis. 21:1989;709-715
8. Zagulski T., Lipinski P., Zagulska A., Broniek S., Jarzabek Z. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br. J. Exp. Pathol. 70:1989;697-704
9. Ellison R.T. III, Giehl T.J., LaForce F.M. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect. Immun. 56:1988;2774-2781
10. Machnicki M., Zimecki M., Zagulski T. Lactoferrin regulates the release of tumour necrosis factor α and interleukin 6 in vivo. Int. J. Exp. Pathol. 74:1993;433-439
11. Kruzel M.L., Harari Y., Mailman D., Actor J.K., Zimecki M. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin. Exp. Immunol. 130:2002;25-31
12. Zimecki, M. and Kruzel, M.L. (2000) Protective effect of lactoferrin against LPS-induced endotoxemia is mediated by IL-10. In: Proceedings, 5th World Conference on Trauma, Shock, Inflammation and Sepsis; Pathophysiology, Immune Consequences and Therapy (Monduzzi Ed.). pp. 221-225
13. Machnicki M., Zimecki M. Bovine lactoferrin prevents lethality of mice treated with recombinant tumor necrosis factor α and galactosamine. Centr. Eur. J. Immunol. 25:2000;76-80
14. Kruzel M.L., Harari Y., Chen C.Y., Castro G.A. The gut. A key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice. Adv. Exp. Med. Biol. 443:1998;167-173
15. Kruzel M.L., Harari Y., Chen C.Y., Castro G.A. Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice. Inflammation. 24:2000;33-44
16. Van Snick J., Cayphas S., Vink A., Uyttenhove C., Coulie P.G., Rubira M.R., Simpson R.J. Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc. Natl. Acad. Sci. USA. 83:1986;9679-9683
17. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods. 119:1989;203-210
18. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods. 95:1986;99-105
19. Marks J.D., Marks C.B., Luce J.M., Montgomery A.B., Turner J., Metz C.A., Murray J.F. Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am. Rev. Resp. Dis. 141:1990;94-97
20. Gallily R., Yamin A., Waksmann Y., Ovadia H., Weidenfeld J., Bar-Joseph A., Biegon A., Mechoulam R., Shohami E. Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J. Pharmacol. Exp. Ther. 283:1997;918-924
21. Yang F., de Villiers W.J., McClain C.J., Varilek G.W. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. J. Nutr. 128:1998;2334-2340
22. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., Mier J.W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 83:1994;113-118
23. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., Achong M.K. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101:1998;311-320
24. Dalrymple S.A., Slattery R., Aud D.M., Krishna M., Lucian L.A., Murray R. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect. Immun. 64:1996;3231-3235
25. Smith S.R., Calzetta A., Bankowski J., Kenworthy-Bott L., Terminelli C. Lipopolysaccharide-induced cytokine production and mortality in mice treated with Corynebacterium parvum. J. Leukoc. Biol. 54:1993;23-29
26. Doherty G.M., Lange J.R., Langstein H.N., Alexander H.R., Buresh C.M., Norton J.A. Evidence for IFN-γ as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. J. Immunol. 149:1992;1666-1670
27. Gerard C., Bruyns C., Marchant A., Abramowicz D., Vandenabeele P., Delvaux A., Fiers W., Goldman M., Velu T. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 177:1993;547-550